Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections (Q38025132)

27 August 2017

title

Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections (English)

1 reference

27 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

Thomas P Lodise

1

1 reference

27 August 2017

Donald E Low

series ordinal

2

1 reference

27 August 2017

publication date

1 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

72

1 reference

27 August 2017

issue

11

1 reference

27 August 2017

page(s)

1473-1493

1 reference

Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Multistep Resistance Development Studies of Ceftaroline in Gram-Positive and -Negative Bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Efficacy of Human Simulated Exposures of Ceftaroline Administered at 600 Milligrams Every 12 Hours against Phenotypically Diverse Staphylococcus aureus Isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. a

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Efficacy of human simulated exposures of ceftaroline against phenotypically diverse Enterobacteriaceae isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

In vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid a

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Effect of ceftaroline on normal human intestinal microflora.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165/11635660-000000000-00000

Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

21 January 2018

1 reference

12 December 2020

Sulphanilamide in the Treatment of Erysipelas

1 reference

12 December 2020

Postantibiotic effect of ceftaroline against gram-positive organisms

1 reference

12 December 2020

Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus

1 reference

12 December 2020

Prontosil in Erysipelas

1 reference

12 December 2020

Synergy, antagonism, and what the chequerboard puts between them

1 reference

12 December 2020

10.2165/11635660-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1019913991

0 references

1 reference